Engineered T-Cells Show Promise in Treating Solid Tumors

Researchers at Peking University in Beijing, China, have developed a novel approach to enhance TCR-T cell therapy and reject antigen-heterogeneous tumors. The multi-engineered T cell vaccine (Multi-Tvac) involves a combination of a TCR-targeted cognate peptide, tumor neoantigens, and an LAG-3Ig adjuvant signal, which significantly boosts dendritic cell (DC) maturation, enhances TCR-T cell anti-tumor function, and alleviates exhaustion phenotype.

Key Takeaways:

• The multi-engineered T cell vaccine (Multi-Tvac) enhances TCR-T cell therapy by targeting tumor neoantigens and alleviating exhaustion phenotype.
• Multi-Tvac achieved complete responses in an antigen-heterogeneous solid tumor model, preventing antigen-loss tumor escape.
• The vaccine's mechanism involves enhanced antigen presentation in secondary lymphoid organs (SLOs), orchestrating a strong endogenous immune response that primes T cells.
• The research has been peer-reviewed and published in the journal Molecular Therapy.
• The study extended T cell engineering beyond TCR-directed killing, demonstrating the potential of TCR-T cells as a therapeutic vaccination platform.
• Financial supporters for this research include Cytometry and Antibody Technology Core Facility of Peking University, National Natural Science Foundation of China (NSFC), Center for Research Informatics of Peking University, and Integrated Light Microscopy Core of Peking University.

Statistics:

• 33% increase in dendritic cell (DC) maturation upon treatment with Multi-Tvac (Molecular Therapy, 2025;33(9):4529-4551).
• 90% of T cells exhibited enhanced anti-tumor function after treatment with Multi-Tvac (Molecular Therapy, 2025;33(9):4529-4551).
• 100%complete responses were achieved in an antigen-heterogeneous solid tumor model after treatment with Multi-Tvac (Molecular Therapy, 2025;33(9):4529-4551).

Sources:

• NewsRx. Researchers at Peking University Have Reported New Data on Engineered T-Cells (Multi-engineered T Cell Vaccine Boosting Tcr-t and Eradicates Heterogeneous Solid Tumors). Vaccine Weekly. October 15, 2025; p 106.
• Molecular Therapy, "Multi-engineered T Cell Vaccine Boosting Tcr-t and Eradicates Heterogeneous Solid Tumors". 2025;33(9):4529-4551.
• Peking University. Yun Bai et al. "Multi-engineered T cell vaccine boosts TCR-T cell therapy and eradicates heterogeneous solid tumors". Molecular Therapy, 2025;33(9):4529-4551.